1.36
Metagenomi Therapeutics Inc Aktie (MGX) Neueste Nachrichten
MGX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineQuarterly Earnings Report - Newser
MGX Q1 2026 Earnings: Missed Expectations as Pre-Revenue Biotech Advances Gene Editing PipelineEarnings Cycle Outlook - Newser
PRN_FinancialWrapper - FinancialContent
Number of shareholders of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50 - MSN
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results - simplywall.st
Metagenomi Therapeutics (MGX) reports Q1 loss, misses revenue estimates - MSN
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MSN Money - MSN
Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy - TipRanks
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics: Q1 Earnings Snapshot - KVUE
Metagenomi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Metagenomi Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Metagenomi (NASDAQ: MGX) details Q1 2026 loss, cash runway and MGX-001 IND plans - Stock Titan
Metagenomi gene edit for hemophilia A targets 2027 human trials - Stock Titan
MGX Stock Price, Quote & Chart | METAGENOMI THERAPEUTICS INC (NASDAQ:MGX) - ChartMill
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
SEC Form DEF 14A filed by Metagenomi Therapeutics Inc. - Quantisnow
[DEF 14A] Metagenomi Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
MGX Price Today: Metagenomi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Metagenomi Therapeutics (MGX) Stock: Sentiment Analysis (Weakens) 2026-04-22Large Cap Trends - Xã Thanh Hà
MGX Financials: Income Statement, Balance Sheet & Cash Flow | Metagenomi Therapeutics, Inc - Stock Titan
A smaller gene editor cut Atxn2 protein 64% in mice, Metagenomi says - Stock Titan
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Eastern Progress
Metagenomi reports compact gene editing tool in Nature journal - Investing.com
What is the valuation of Metagenomi Therapeutics (MGX) Stock | Price at $1.39, Up 0.72%Expert Market Insights - Newser
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
MGX: Metagenomi Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
Metagenomi Can’t Ax IPO Investor Suit Over Moderna Partnership - Bloomberg Law News
If You Invested $1,000 in Metagenomi Therapeutics, Inc (MGX) - Stock Titan
Metagenomi Therapeutics Fiscal Results: Q4 Loss of $22.5M, Annual Loss $87.9MNews and Statistics - IndexBox
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics: Q4 Earnings Snapshot - kens5.com
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results - Bitget
Metagenomi Therapeutics Q4 Earnings Assessment - Benzinga
MGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MGX Technical Analysis & Stock Price Forecast - Intellectia AI
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference - The Manila Times
Metagenomi Therapeutics, Inc. CEO Jian Irish to Speak at 46th Annual TD Cowen Healthcare Conference - Quiver Quantitative
Gene-editing firm Metagenomi CEO in TD Cowen fireside chat - Stock Titan
MGXMetagenomi Therapeutics, Inc Latest Stock News & Market Updates - Stock Titan
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Head to Head Analysis: Acusphere (OTCMKTS:ACUS) and Metagenomi (NASDAQ:MGX) - Defense World
Xeris Biopharma (NASDAQ:XERS) and Metagenomi (NASDAQ:MGX) Critical Comparison - Defense World
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):